about
Pathogenic potential of novel Chlamydiae and diagnostic approaches to infections due to these obligate intracellular bacteriaPlasma concentrations of chloramphenicol after subcutaneous administration to koalas (Phascolarctos cinereus) with chlamydiosisImpact of azithromycin resistance mutations on the virulence and fitness of Chlamydia caviae in guinea pigs.Enrofloxacin and macrolides alone or in combination with rifampicin as antimicrobial treatment in a bovine model of acute Chlamydia psittaci infection.Spider venom peptides for gene therapy of Chlamydia infection.Psittacosis infection and tracheobronchomalacia in a patient undergoing thyroidectomy.Prevalence of chlamydia among HIV positive and HIV negative patients in the Vhembe District as detected by real time PCR from urine samples.Differences in 23S ribosomal RNA mutations between wild-type and mutant macrolide-resistant Chlamydia trachomatis isolates.Frequency of development and associated physiological cost of azithromycin resistance in Chlamydia psittaci 6BC and C. trachomatis L2.Transformation and isolation of allelic exchange mutants of Chlamydia psittaci using recombinant DNA introduced by electroporation.Antibiotic susceptibility of Waddlia chondrophila in Acanthamoeba castellanii amoebae.Genital Chlamydia trachomatis: understanding the roles of innate and adaptive immunity in vaccine research.Simkania negevensis, an Example of the Diversity of the Antimicrobial Susceptibility Pattern among Chlamydiales.Treatment of Chlamydial infections: 2014 update.Recent advances in technologies for developing drugs against Chlamydia pneumoniae.Cyto-Insectotoxin 1a from Lachesana tarabaevi Spider Venom Inhibits Chlamydia trachomatis Infection.Treatment of chlamydial infections.Review of some pharmacokinetic and pharmacodynamic properties of anti-infective medicines administered to the koala (Phascolarctos cinereus).
P2860
Q24545825-36B7F122-7876-4C63-A076-F19D67A25AB0Q29398804-1826D957-B45E-4AA1-A84A-B044C4D88D9BQ33676306-C1B4C03B-D152-4332-8393-7D943758C0F3Q35175244-94FA3538-6CF0-4747-9C70-6AAB0C34CC38Q35364271-F9E4C380-3CBA-4134-ABD5-FF0286F218EBQ35519532-736398A7-1E41-4F86-9214-338CAC7769A0Q35924303-CADB85CE-24B0-4509-B099-84D8764C7061Q35942887-F5FFB60E-5CFF-4DE0-AC6F-AC2C4DC885DDQ36313199-7C6F7CE5-B134-4C17-AC74-36244EC2D9FCQ37068255-E5A9BF47-6256-4D94-8F8C-6C84E36B182DQ37204183-16EA94A8-89B0-45EE-8805-A84A2C9A6807Q37712799-65E6C7CE-81CC-478A-9550-912B1E58CD7BQ37834062-8A6CF011-5CC1-42FE-807A-37766D6BD5B5Q37842306-561CB2C9-1957-4770-ADBC-8684D9F88D84Q37844406-7C351371-DD82-436B-8FB4-E1EB79D4E29DQ37848192-A76CD3A3-9FAF-4DAC-A7DF-85B6A038EFEEQ37849351-D8BB927E-01A4-484E-BCEA-FAD54B18C976Q39432406-42546DB0-073E-405C-A06A-6F38FA715B50
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Therapeutic approaches to Chlamydia infections.
@ast
Therapeutic approaches to Chlamydia infections.
@en
type
label
Therapeutic approaches to Chlamydia infections.
@ast
Therapeutic approaches to Chlamydia infections.
@en
prefLabel
Therapeutic approaches to Chlamydia infections.
@ast
Therapeutic approaches to Chlamydia infections.
@en
P2860
P1476
Therapeutic approaches to Chlamydia infections.
@en
P2093
Margaret R Hammerschlag
P2860
P304
P356
10.1517/14656566.6.13.2281
P407
P577
2005-10-01T00:00:00Z